<DOC>
	<DOCNO>NCT02731131</DOCNO>
	<brief_summary>This single-center , randomize , open-label , pilot study design evaluate efficacy safety 48 week treatment peginterferon alfa-2a alone versus combination ribavirin participant CHD .</brief_summary>
	<brief_title>A Study Peginterferon Alfa-2a With Without Ribavirin Participants With Chronic Hepatitis D ( CHD )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Positive hepatitis B surface antigen ( HBsAg ) prior 6 month Positive antidelta prior 3 month Positive HDV RNA Screening Elevated ALT ( 1 10 time upper limit normal ) prior first dose Chronic , necroinflammatory hepatitis document within prior 18 month ( noncirrhotic ) 30 month ( cirrhotic ) Negative pregnancy adequate contraceptive use Antiviral therapy CHD within previous 3 month Positive hepatitis A C , human immunodeficiency virus ( HIV ) Increased risk metabolic liver disease Decompensated liver disease Elevated bilirubin Poor hematologic renal function Drug/alcohol abuse within 1 year prior study History significant psychiatric , autoimmune , pulmonary , cardiac , oncologic , thyroid disease Organ transplantation exist functional graft Retinopathy ophthalmologic complication diabetes hypertension Inclusion another investigational trial within previous 12 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>